Social challenges
RAYUELA
RAYUELA aims to better understand the drivers and human factors affecting certain relevant ways of cyber criminality, as well as...

Treatment
A new approach to treating Polyendocrine Metabolic Ovarian Syndrome (PMOS) in adolescents and young women

Project dates
2021 - 2026
Website
Role of Zabala
Partner
Project led by
Fundació Sant Joan de Déu
17
Partners
9
Countries
6 M€
Total budget
5
Years
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is one of the most common endocrine disorders affecting women of reproductive age and one of the leading causes of infertility.
Despite its high prevalence, current treatments focus primarily on managing symptoms rather than addressing the underlying causes of the syndrome.
This limitation, combined with the complexity and variability of PMOS, makes the condition particularly challenging to manage, especially in adolescents and young women, and may lead to long-term complications.
In this context, SPIOMET4HEALTH aims to advance towards a treatment approach based on the mechanisms underlying the syndrome.
SPIOMET4HEALTH proposes an innovative approach focused on the pathophysiology of the syndrome through the development and validation of a specific therapeutic combination in a single formulation.
The project is evaluating a treatment that targets the metabolic and hormonal mechanisms involved in PMOS, with the aim of providing a more effective alternative to current approaches.
This approach represents a step towards treatments that address the underlying causes of the syndrome, with the potential to improve patients’ quality of life.
The project brings together a multidisciplinary consortium of research centres, hospitals and specialised healthcare organisations from several European countries. As part of the project, a multicentre clinical trial has been conducted in Spain, Italy, Denmark, Austria, Norway and Türkiye, generating a robust body of data on the efficacy and safety of the treatment across a diverse patient population.
These results will help validate a new therapeutic approach and improve the management of PMOS in clinical practice.

Zabala Innovation participates in SPIOMET4HEALTH as the partner responsible for communication and dissemination. Its contribution focuses on:
At Zabala Innovation, we support organisations in the development of European projects, from proposal design through to the communication and exploitation of results.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme, under grant agreement No. 899671.

“SPIOMET4Health is proposed by a consortium of the highest-profile groups working on PMOS in adolescent girls and young adults (AYAs); this project offers the EU a unique opportunity to enable a robust attempt to generate medical benefits for patients with PMOS.”
Laura Sesma
Team leader expert in European Programmes in the Health Area
Celebration of International Clinical Trials Day of the SPIOMET4HEALTH project
Third general assembly of the SPIOMET4HEALTH project
Recruitment for the SPIOMET4HEALTH project has been completed
New article of the SPIOMET4HEALTH project
Launch of the SPIOMET4HEALTH Project
SPIOMET4HEALTH moves towards the first treatment for polycystic ovary syndrome
















Social challenges
RAYUELA aims to better understand the drivers and human factors affecting certain relevant ways of cyber criminality, as well as...
Mobility
The main objective of RECET4Rail is to introduce new emerging and disruptive technologies in the railway sector to improve the...
Energy
The general objective of PLAN4CET is to support European regions and cities to design, develop, and implement CET plans according...

News
LIFE 2021-2027
The first calls are now available on the Funding and Tenders Portal.

Opinion
INVESTEU

InvestEU Team
EXPERTS IN THE INVESTEU PROGRAMME

Publication
MFP 2028–2034
An in-depth analysis of its strategic reconfiguration and its impact on competitiveness, scaling and technological autonomy, in comparison with the models and dynamics of China and the United States
Lo importante no es seguir avanzando, sino saber hacia dónde ir. Y nuestra tasa de éxito del 37% demuestra que en Zabala sabemos guiar a nuestros clientes.
Nuestra brújula es el cliente; nuestra misión es resolver sus problemas, guiándole para que la innovación se convierta en su clave de competitividad.
